Business
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ― ― Dosed first patient in an open-label, long-term dosing trial evaluating the long-term safety and durability of response to pociredir in participants previously enrolled in
About this update from Fulcrum Therapeutics, Inc.
[{"type":"image","alt":"Fulcrum Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Fulcrum Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/b2436aacd8d6614fd2b1c157e4f5cc27"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AHcGLitrcyTwdxVaaq006w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMg--/https://media.zenfs.com/en/globenewswire.com/b2436aacd8d6614fd2b1c157e4f5cc27","width":300,"height":73}},"lazy":false},{"type":"text","content":"― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ―","length":229,"tagName":"p"},{"type":"text","content":"― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ―","length":96,"tagName":"p"},{"type":"text","content":"― Dosed first patient in an open-label, long-term dosing trial evaluating the long-term safety and durability of response to pociredir in participants previously enrolled in the PIONEER trial ―","length":193,"tagName":"p"},{"type":"text","content":"― Appointed Josh Lehrer, M.D., M.Phil., FACC, an experienced leader in sickle cell disease drug development, to the Board of Directors ―","length":136,"tagName":"p"},{"type":"text","content":"― Chief Financial Officer, Alan Musso plans to retire later this year and will continue in his role until a successor is named ―","length":128,"tagName":"p"},{"type":"text","content":"― Ended the first quarter of 2026 with $333.3 million in cash, cash equivalents, and marketable securities; cash runway into 2029 ―","length":131,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of patients with rare hematological disorders, today reported financial results for the first quarter of 2026 and provided a business update.","length":352,"tagName":"p"},{"type":"text","content":"“The strength of the clinical data presented in the first quarter further reinforce our conviction in pociredir’s potential to address the underlying biology of sickle cell disease...